title: Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial.
abstract: OBJECTIVE
  To compare the efficacy of intravaginal and IMP for luteal phase support in IVF cycles.
  
  
  METHODS
  Prospective trial.
  
  
  METHODS
  Tertiary care private practice.
  
  
  METHODS
  Women 25-44 years old with infertility necessitating treatment with IVF. From April 1, 2008-April 1, 2009, 511 consecutive patients were enrolled; 474 completed participation, and 37 were excluded for no autologous ET (freeze all, donor recipients, failed fertilization/cleavage). There were no demographic differences between the two treatment groups.
  
  
  METHODS
  Luteal phase support using either Crinone or P in oil starting 2 days following oocyte retrieval.
  
  
  METHODS
  Pregnancy and delivery rates stratified by patient age.
  
  
  RESULTS
  Overall, patients who received vaginal P had higher pregnancy (70.9% vs. 64.2%) and delivery (51.7% vs. 45.4%) rates than did patients who received IMP. Patients <35 who received vaginal P had significantly higher delivery rates (65.7% vs. 51.1%) than did patients who received IMP. There were no differences, regardless of age, in the rates of biochemical pregnancy, miscarriage, or ectopics.
  
  
  CONCLUSIONS
  In younger patients undergoing IVF, support of the luteal phase with Crinone produces significantly higher pregnancy rates than does IMP. Crinone and IMP appear to be equally efficacious in the older patient.
authors.affiliation: Texas Fertility Center and Austin IVF, Austin, Texas. kaylen@txfertilty.com
authors.forename: Kaylen M
authors.initials: KM
authors.lastname: Silverberg
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Vaughn
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Hansard
authors.forename: Natalie Z
authors.initials: NZ
authors.lastname: Burger
authors.forename: Tamara
authors.initials: T
authors.lastname: Minter
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000367:Age Factors; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D005307:Fertilization in Vitro / Q000009:adverse effects; D006801:Humans; D007246:Infertility / Q000503:physiopathology / Q000628:therapy*; D007273:Injections, Intramuscular; D008183:Luteal Phase / Q000187:drug effects*; D009821:Oils; D054315:Oocyte Retrieval; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011446:Prospective Studies; D013781:Texas; D016896:Treatment Outcome; D014622:Vaginal Creams, Foams, and Jellies
chemical_list: C400424:Crinone; D005300:Fertility Agents, Female; D009821:Oils; D014622:Vaginal Creams, Foams, and Jellies; D011374:Progesterone